196 related articles for article (PubMed ID: 34253674)
1. Retrospective cohort analysis of prescription patterns of cancer medications during periods of drug stockouts in Botswana.
Davey S; Grover S; Bilker WB; Setlhako DI; Ralefala TB; Manshimba P; Gross R; DeMichele A; Shulman LN; Martei YM
BMJ Open; 2021 Jul; 11(7):e049574. PubMed ID: 34253674
[TBL] [Abstract][Full Text] [Related]
2. Vaccine stockouts around the world: Are essential vaccines always available when needed?
Lydon P; Schreiber B; Gasca A; Dumolard L; Urfer D; Senouci K
Vaccine; 2017 Apr; 35(17):2121-2126. PubMed ID: 28364919
[TBL] [Abstract][Full Text] [Related]
3. Provider Barriers and Facilitators of Breast Cancer Guideline-Concordant Therapy Delivery in Botswana: A Consolidated Framework for Implementation Research Analysis.
Ralefala T; Mokokwe L; Jammalamadugu S; Legobere D; Motlhwa WS; Oyekunle AA; Grover S; Barg FK; Shulman LN; Martei YM
Oncologist; 2021 Dec; 26(12):e2200-e2208. PubMed ID: 34390287
[TBL] [Abstract][Full Text] [Related]
4. Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting.
Martei YM; Grover S; Bilker WB; Monare B; Setlhako DI; Ralefala TB; Manshimba P; Gross R; Shulman LN; DeMichele A
J Glob Oncol; 2019 Apr; 5():1-11. PubMed ID: 30969808
[TBL] [Abstract][Full Text] [Related]
5. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
6. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
7. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
Weycker D; Barron R; Edelsberg J; Kartashov A; Lyman GH
Breast Cancer Res Treat; 2012 May; 133(1):301-10. PubMed ID: 22270932
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of Australia's Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008-2012.
Harris C; Daniels B; Ward RL; Pearson SA
Public Health Res Pract; 2017 Dec; 27(5):. PubMed ID: 31044212
[TBL] [Abstract][Full Text] [Related]
9. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
Gadisa DA; Assefa M; Wang SH; Yimer G
J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
[TBL] [Abstract][Full Text] [Related]
10. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer patient experiences in the Botswana health system: Is it time for patient navigators?
Sharma K; Baghirova-Busang L; Abkenari S; Gulubane G; Rana C; Vuylsteke P; Marlink R; Gaolathe T; Masupe T
J Cancer Policy; 2023 Dec; 38():100449. PubMed ID: 37890667
[TBL] [Abstract][Full Text] [Related]
13. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
14. Stigma and Social Determinants of Health Associated With Fidelity to Guideline-Concordant Therapy in Patients With Breast Cancer Living With and Without HIV in Botswana.
Martei YM; Obasohan M; Mokokwe L; Ralefala T; Mosepele M; Gross R; Barg FK
Oncologist; 2023 Dec; 28(12):e1230-e1238. PubMed ID: 37405697
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel: an update of its use in advanced breast cancer.
Figgitt DP; Wiseman LR
Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy and pathologic response: a retrospective cohort.
Andrade DA; Zucca-Matthes G; Vieira RA; Andrade CT; Costa AM; Monteiro AJ; Dal Lago L; Nunes JS
Einstein (Sao Paulo); 2013 Dec; 11(4):446-50. PubMed ID: 24488382
[TBL] [Abstract][Full Text] [Related]
18. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Davidson NE
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
[TBL] [Abstract][Full Text] [Related]
19. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
van Dooijeweert C; van der Wall E; Baas IO
Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
